J9324 NDC Crosswalk, Billing Units, ASP Payment & Medicare Reimbursement

📋 J9324 summary

J9324 is a HCPCS Level II J-code used to bill pemetrexed (pemrydi rtu), 10 mg, billed per 10 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with J9324: Pemrydi Rtu

Code J9324 Billing unit 10 MG Payment limit $67.935/unit NDC-Crosswalk 2 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ9324

DescriptorInjection, pemetrexed (pemrydi rtu), 10 mg

Billing unit10 MG

Payment limit / unit$67.935

Est. ASP / unit$64.090 est.

Mapped NDCs2

Data periodQ3 2026

Last updated2026-08-20

💊 About Pemetrexed Disodium DRUG GUIDE

Pemetrexed disodium injection is used to treat two types of cancer: non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (a cancer of the lining around the lungs).

It is available under several brand and generic names, including Alimta, Pemrydi RTU, and generic pemetrexed products.For non-squamous NSCLC, it can be used in combination with pembrolizumab and platinum chemotherapy as initial treatment for metastatic disease (in patients without certain genetic mutations), with cisplatin as initial treatment for locally advanced or metastatic disease, as a single-agent maintenance treatment after first-line platinum-based chemotherapy, or as a single agent after prior chemotherapy.

It is also used with cisplatin as initial treatment for malignant pleural mesothelioma that cannot be surgically removed.

It is not approved for squamous cell non-small cell lung cancer.

Read the full Pemetrexed Disodium drug guide →

Clinical overview from our editorial drug guide for Pemetrexed Disodium. For billing reference, see the sections above.

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).

Medicare payment limit / unit

$67.935

Est. ASP / unit

$64.090 est.

Est. after 2% sequester

$66.576

HCPCS dosage

10 MG

The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.

Full HCPCS code details (official CMS record)

Long descriptionInjection, pemetrexed (pemrydi rtu), 10 mg

CoverageC — Carrier/MAC judgment

Pricing indicator51 — Drug — priced under the ASP methodology

Type of service1 — Medical care

BETOS-2O1E

ASC payment group—

Action codeA — Added this year

Effective date2024-01-01

Date added2024-01-01

Source: CMS HCPCS Level II code file (imported via admin).

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J9324 = 10 mg. Enter a regimen to convert dose → billing units and project a full course.

Dose per administration (mg) Frequency — every days Number of doses NDC / package billed (optional)

Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J9324 WITH EST. MEDICARE PAY

2 NDCs map to J9324. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($67.935/unit) × that package's bill units.

NDC (11-digit)	Drug	Labeler	Package	Strength	Bill units	Est. pay / pkg	NADAC / unit	Status	Source
70121-2453-01	PEMRYDI RTU Pemetrexed disodium 100 mg/10mL INJECTION	Amneal	1 VIAL in 1 CARTON (70121-2453-1) / 10 mL...	100 mg/10mL	10	$679.35	—	● Active	CMS ASP
70121-2461-01	PEMRYDI RTU Pemetrexed disodium 500 mg/50mL INJECTION	Amneal	1 VIAL in 1 CARTON (70121-2461-1) / 50 mL...	500 mg/50mL	50	$3,396.75	—	● Active	CMS ASP

NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

⚠️ Don't confuse J9324 with… RELATED CODES

Adjacent HCPCS codes that share an ingredient or formulation with J9324. Billing units and payment limits differ — confirm the exact code, strength and form before billing.

Code	Descriptor	Billing unit	Payment limit / unit	How it differs from J9324
J9304	Inj. pemetrexed, 10 mg	10 MG	$7.994	Related ingredient or formulation — confirm strength, form and billing unit before substituting.
J9305	Inj. pemetrexed nos 10mg	10 MG	$6.952	Related ingredient or formulation — confirm strength, form and billing unit before substituting.
J9292	PEMETREXED DIPOTASSIUM	10 MG	$73.670	Related ingredient or formulation — confirm strength, form and billing unit before substituting.
J9294	Inj pemetrexed, hospira 10mg	10 MG	$2.943	Related ingredient or formulation — confirm strength, form and billing unit before substituting.
J9314	Inj pemetrexed (teva) 10mg	10 MG	$10.986	Related ingredient or formulation — confirm strength, form and billing unit before substituting.
J9323	Inj pemetrexed ditromethamin	—	—	Related ingredient or formulation — confirm strength, form and billing unit before substituting.

Related codes matched on shared ingredient (CMS Medicare Part B Spending feed). Billing units and payment limits from the CMS ASP Pricing File. Always verify the precise HCPCS code for the product and strength administered.

📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)

Period

Total Part B spend

$5.46M

Claims

903

Beneficiaries

406

Spend / beneficiary

$13,443.14

Spend / claim

$6,044.20

Trend by period

Where J9324 ranks among Part B drugs · 2026 (Q1) · neighbors ±5

Total spending — #233 of 824

#228 CAMCEVI J1952 $5.75M #229 VIVIMUSTA J9056 $5.63M #230 ORTHOVISC J7324 $5.56M #231 BUDESONIDE* J7626 $5.49M #232 CABENUVA J0741 $5.49M #233 PEMRYDI RTU J9324 $5.46M #234 STIMUFEND Q5127 $5.42M #235 FOLOTYN* J9307 $5.4M #236 NOVOSEVEN RT J7189 $5.33M #237 CUTAQUIG J1551 $5.29M #238 COSELA J1448 $5.14M

Total claims — #385 of 824

#380 BLINCYTO J9039 933 #381 MANNITOL(J2151) J2151 925 #382 BEOVU J0179 920 #383 CABENUVA J0741 920 #384 ORPHENADRINE CITRATE J2360 916 #385 PEMRYDI RTU J9324 903 #386 ENJAYMO J1302 892 #387 ASTAGRAF XL J7508 883 #388 PIPERACILLIN-TAZOBAC... J2543 873 #389 AMIKACIN SULFATE J0278 865 #390 LUMASON Q9950 846

Full breakdown by period (2)

Period	Total spend	Beneficiaries	Claims	$/beneficiary	$/claim
2026 (Q1)	$5.46M	406	903	$13,443.14	$6,044.20
2025 (Q1-Q4)	$10.25M	483	1,574	$21,215.15	$6,510.11

Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📈 Medicare Part B claims detail CMS PSPS · 2024

Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.

Allowed charges

$10.14M

Medicare paid

$7.92M

Submitted services

150,909

Denial rate

13.7%

Allowed / service

$77.87

Submitted charges

$29.96M

Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.

🗺️ Where J9324 is utilized

⏳

The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.

HCPCS code & descriptor

CMS HCPCS Level II code file

Loaded

Payment limit & billing unit

CMS Medicare Part B ASP Pricing File (quarterly)

Q3 2026 · as of 2026-08-20

NDC ↔ HCPCS crosswalk

CMS ASP NDC-HCPCS crosswalk

2 NDCs mapped

NADAC acquisition cost

CMS National Average Drug Acquisition Cost (weekly)

Not available for mapped NDCs

Utilization & spend

CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners

Latest data year 2026

Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J9324 billing FAQ

What is HCPCS code J9324?

J9324 is a HCPCS Level II J-code used to bill Injection, pemetrexed (pemrydi rtu), 10 mg under Medicare Part B and most medical (not pharmacy) benefits.

What is the billing unit for J9324?

One unit of J9324 represents 10 MG. Report the number of units equal to the dose administered divided by 10 MG.

How many units of J9324 should I bill?

Divide the dose administered by the code's unit size (10 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.

How much does Medicare pay for J9324?

The Medicare Part B payment limit is $67.935 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $66.576 per unit. Payment limits are revised quarterly.

Which NDCs bill under J9324?

2 NDCs currently map to J9324 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.

Does a crosswalk mean J9324 is covered?

No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.

J9324 – Injection, pemetrexed (pemrydi rtu), 10 mg · NDC Crosswalk & Billing Units